ERC PHARMA ALPHA
Timeline
41 events since 1996Board
Capital
Filings
Financial
Establishments
Other
200020052010201520202025
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 61 days late
2025
Annual accounts 2024 filed PDFmicro format · 26 days late
Permanent representatives: Mohamad KASSAS and Apostolos STATHOPOULOSGeneral meeting of 16-01-20253 points ▸
- General meeting, 16-01-2025
- Permanent representative, Mohamad KASSAS
- Permanent representative, Apostolos STATHOPOULOS
2024
Weakest financial year net -€63,106 The net result drops to -€63,106, the lowest from 2006 to 2025. It recovers the following year.
Annual accounts 2023 filed PDFmicro format · 138 days late
Company renamed from PHARMACIE ZOMBEK to ERC PHARMA ALPHA2 points ▸
- Name change, ERC PHARMA ALPHA
- Amendment of the articles, article 1
- The deed holds 3 more points.
2023
Equity above €500,000 equity €592,131 ▲19.7% Equity rises from €494,551 to €592,131.
1 director appointed, 1 resignationResignation: Eliane ZOMBEK · Appointment: ERC PHARMA · Permanent representative: Mohamad KASSAS · General meeting of 15-11-20234 points ▸
- General meeting, 15-11-2023
- Director resignation, Eliane ZOMBEK
- Director appointment, ERC PHARMA
- Permanent representative, Mohamad KASSAS
Annual accounts 2022 filed PDFfull format · 56 days late
2022
Annual accounts 2021 filed PDFfull format · 23 days late
2021
Highest result from 2006 to 2025 net €148,550 ▲71.6% The operating result of €194,741 and the net result of €148,550 are both a record.
Annual accounts 2020 filed PDFfull format · 17 days late
2020
Annual accounts 2019 filed PDFfull format · 28 days late
2019
Annual accounts 2018 filed PDFfull format · 58 days late
Capital decrease of €87,750 to €18,592.01Capital from €106,342.01 to €18,592.01 · Change of role: ZOMBEK Eliane, from manager to director · Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 07-08-20197 points ▸
- General meeting, 07-08-2019
- Capital decrease, €87,750
- Legal-form conversion, from private limited company (pre-2019) to private limited company
- Registered office clause, 316, 1090 Jette - Rue Léopold I
- 750 shares
- Director resignation, ZOMBEK Eliane (manager)
- Director appointment, ZOMBEK Eliane (director (not named in the articles))
- The deed holds 5 more points.
2018
Annual accounts 2017 filed PDFfull format · 29 days late
2017
Equity above €200,000 equity €210,407 ▲10.2% Equity rises from €190,916 to €210,407.
Annual accounts 2016 filed PDFfull format · 29 days late
2016
Annual accounts 2015 filed PDFfull format · 4 days before the deadline
2015
Annual accounts 2014 filed PDFfull format · 28 days late
2014
Equity above €150,000 equity €170,009 ▲29% Equity rises from €131,828 to €170,009.
Annual accounts 2013 filed PDFfull format · 3 days before the deadline
2013
Annual accounts 2012 filed PDFfull format · 11 days before the deadline
2012
Annual accounts 2011 filed PDFfull format · on the deadline day
2011
New establishment in Uccle Alsembergsesteenweg 623
Annual accounts 2010 filed PDFfull format · 85 days late
2010
Annual accounts 2009 filed PDFfull format · 76 days late
2009
Annual accounts 2008 filed PDFfull format · 76 days late
2008
Annual accounts 2007 filed PDFfull format · 60 days late
2007
Annual accounts 2006 filed PDFfull format · 59 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2001
Annual accounts 2000 filed PDFfull format
1998
Annual accounts 1997 filed PDFfull format
1997
Incorporation published on 15-01-1997
1996
First establishment Leopold I straat 316, Jette
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
ERC PHARMA ALPHA was incorporated on 7 January 1997.1 Since 2024 the company has been called ERC PHARMA ALPHA.2 ERC Pharma is director of the company, appointed by deed of 15-12-2023.3 Total assets rose from €499,616 in 2018 to €880,509 in 2025 and headcount from 3.8 to 3.4 full-time equivalents.4